Why the study?
Does pharmacotherapy prevent morbidities in patients with prehypertension?
Does pharmacotherapy prevent morbidities in patients with prehypertension?
Emerging evidence links prehypertension with morbidities, supporting the need for pharmacotherapy despite the lack of randomized clinical trials.
Observational links support exploring pharmacotherapy in prehypertension; leaves open morbidity prevention without randomized trials.
In 2009, Blood Pressure featured a debate about whether to treat patients with prehypertension (Kiely et al., Blood Press. 2009;18:300-303; McInnes GT, Blood Press. 2009;18:304-307). Our group supported pharmacotherapy for this condition at that time. Since then, additional evidence linking prehypertension with associated morbidities has emerged. These studies are detailed below and provide further evidence for the treatment of prehypertension.
No takes yet. Share an insight, caveat, or question.
Reed et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: